Type 2 diabetes affects 1 in 10 adults in the United States, and proper treatment is key to preventing complications and improving quality of life.
However, adhering to treatment can be challenging. Thirty-five percent (35%) of patients with type 2 diabetes struggle to stick to their blood sugar-lowering medication, according to research in the journal Clinical Therapeutics.[1]
Poor adherence is often linked to financial burden. A study in the journal Diabetes Care found that approximately 18% of individuals with diabetes reported cost as a factor in their inability to take their medications.[2]
That means that affordable and accessible medicines can significantly improve the overall health of people with diabetes. A treatment called BRENZAVVY (bexagliflozin) aims to meet this need at a much lower price compared to other heavily advertised treatments in the same class.
“I’m encouraged by the evolution of the supporting data for BRENZAVVY,” said Brian Connelly, CEO of TheracosBio, “and believe that [the Diabetes Care] study confirms that BRENZAVVY can serve as a cost-effective treatment option for millions of patients with type 2 diabetes mellitus. We do not think patients should have to compromise on efficacy or safety when they receive a more affordable option.”
BRENZAVVY is FDA-approved to help manage blood sugar levels in people with type 2 diabetes when used with diet and exercise modifications. BRENZAVVY belongs to the drug class oral sodium-glucose transporter 2 (SGLT2) inhibitors and is not approved for use in people with type 1 diabetes. The adverse reactions across clinical trials are typical for this drug class. The most common reactions (incidence >5%) are female genital mycotic infections, urinary tract infection, and increased urination.
BRENZAVVY is available at local independent and online pharmacies, which can be convenient for both patients and providers.
To learn more and for the full Prescribing Information, visit brenzavvy.com
[1] Yang et al., 2009; Clinical Therapeutics 31(10) 2178-2188
[2] Taha et al., 2022; Diabetes Care 45(3) 594-603
